Compare Equinix Inc (EQIX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Illumina, Inc. — how do they compare? Equinix Inc trades at $1,041.96 (market cap $101.87B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Equinix Inc is far larger — about 3.5× Illumina, Inc.'s market cap, and Equinix Inc pays a 2% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| EQIX | ILMN | |
|---|---|---|
Market Cap | $101.87B | $29.12B |
Sector | Real Estate | Health |
52-Week High | $1.12K | $205.10 |
52-Week Low | $726.09 | $91.00 |
Enterprise Value | $123.00B | $30.48B |
Dividend Yield | 2% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
